TY - JOUR
T1 - Real-World Impact of SABR on Stage I Non-Small Cell Lung 2 Cancer Outcomes at a Scottish Cancer Centre
AU - Edinburgh Cancer Informatics Programme
AU - Stares, Mark
AU - Lewis, Georgina
AU - Vallet, Maheva
AU - Killean, Angus
AU - Tramonti, Giovanni
AU - Patrizio, Ailsa
AU - Mackean, Melanie J
AU - Harrow, Stephen
AU - Barrie, Colin
AU - Maclennan, Kirsty
AU - Campbell, Sorcha
AU - Evans, Tamasin
AU - Tufail, Aisha
AU - Hall, Peter S
AU - Phillips, Iain
N1 - Funding Information:
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/2/23
Y1 - 2023/2/23
N2 - Abstract: Introduction: Stereotactic ablative body radiotherapy (SABR) offers patients with stage I 28 non small-cell lung cancer (NSCLC) a safe, effective radical therapy option. The impact of introduc-29 ing SABR at a Scottish regional cancer centre was studied. Methods: The Edinburgh Cancer Centre 30 Lung Cancer Database was assessed. Treatment patterns and outcomes were compared across treat-31 ment groups (no radical therapy (NRT), conventional radical radiotherapy (CRRT), SABR and sur-32 gery) and across 3 time periods reflecting the availability of SABR (A, January 2012/2013 (pre-33 SABR); B, 2014/ 2016 (introduction of SABR); C, 2017/2019, (SABR established). Results: 1143 pa-34 tients with stage I NSCLC were identified. Treatment was NRT in 361 (32%), CRRT in 182 (16%), 35 SABR in 132 (12%) and surgery in 468 (41%) of patients. Age, performance status and comorbidities 36 correlated with treatment choice. Median survival increased from 32.5 months in time period A to 37 38.8 months in period B to 48.8 months in time period C. The greatest improvement in survival was 38 seen in patients treated with surgery between time periods A and C (HR 0.69 (95%CI 0.56-0.86), 39 p
AB - Abstract: Introduction: Stereotactic ablative body radiotherapy (SABR) offers patients with stage I 28 non small-cell lung cancer (NSCLC) a safe, effective radical therapy option. The impact of introduc-29 ing SABR at a Scottish regional cancer centre was studied. Methods: The Edinburgh Cancer Centre 30 Lung Cancer Database was assessed. Treatment patterns and outcomes were compared across treat-31 ment groups (no radical therapy (NRT), conventional radical radiotherapy (CRRT), SABR and sur-32 gery) and across 3 time periods reflecting the availability of SABR (A, January 2012/2013 (pre-33 SABR); B, 2014/ 2016 (introduction of SABR); C, 2017/2019, (SABR established). Results: 1143 pa-34 tients with stage I NSCLC were identified. Treatment was NRT in 361 (32%), CRRT in 182 (16%), 35 SABR in 132 (12%) and surgery in 468 (41%) of patients. Age, performance status and comorbidities 36 correlated with treatment choice. Median survival increased from 32.5 months in time period A to 37 38.8 months in period B to 48.8 months in time period C. The greatest improvement in survival was 38 seen in patients treated with surgery between time periods A and C (HR 0.69 (95%CI 0.56-0.86), 39 p
KW - Non small cell lung cancer
KW - stage 1
KW - stereotactic ablative radiotherapy
KW - real-world clinical data
U2 - 10.3390/cancers15051431
DO - 10.3390/cancers15051431
M3 - Article
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 5
M1 - 1431
ER -